Incentivizing Drug Development in Serious Mental Illness
Related Experiment Video
Updated: Aug 30, 2025

Development of a Virtual Reality Assessment of Everyday Living Skills
Published on: April 23, 2014
Hannah Geils1, Abigail Riley1, Tara A Lavelle1
1Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, Massachusetts.
Abstract:
Serious mental illness (SMI) imposes a significant burden on individuals and society. Individuals living with SMI have worse expected health, education, and career outcomes during their lifetime. Although treatments exist, pharmaceutical innovation in this area has lagged many other disease areas, despite an important need for new treatments. This report describes barriers that have hindered innovation and the development of new drugs for SMI, including science and research, regulatory, and health system barriers. To address these barriers, this report presents policies that may incentivize investment in this area.
Related Concept Videos
Drug Therapy
Antianxiety Medications
Psychosis: Goals of Pharmacotherapy
Antidepressant Drugs: MAOIs and Other Agents
Clinical Trials: Overview
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Drug Discovery: Overview

